Francois Brisebois
Stock Analyst at Oppenheimer
(1.76)
# 3,347
Out of 5,157 analysts
74
Total ratings
37.84%
Success rate
-0.23%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $95 → $105 | $73.02 | +43.80% | 8 | Feb 25, 2026 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $4.20 | +90.48% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.61 | +6.95% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $30.00 | +166.67% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.14 | +211.28% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $2.13 | +87.79% | 1 | Jan 29, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $28.74 | +112.25% | 6 | Jan 13, 2025 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $13.20 | +112.12% | 2 | Nov 6, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $309.91 | -47.40% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $19.78 | +178.06% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.29 | +5,003.78% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $7.95 | -24.53% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.28 | +157.01% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $27.59 | -49.26% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $12.26 | +430.18% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.01 | +99.60% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.37 | +107.25% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.92 | +51,269.86% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.13 | +477,776.11% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $1.83 | +501.09% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.34 | +438.92% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $7.44 | +572.04% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.61 | +528,793.24% | 1 | Feb 4, 2020 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $95 → $105
Current: $73.02
Upside: +43.80%
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $4.20
Upside: +90.48%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.61
Upside: +6.95%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $30.00
Upside: +166.67%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.14
Upside: +211.28%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $2.13
Upside: +87.79%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $28.74
Upside: +112.25%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $13.20
Upside: +112.12%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $309.91
Upside: -47.40%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $19.78
Upside: +178.06%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.29
Upside: +5,003.78%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $7.95
Upside: -24.53%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.28
Upside: +157.01%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $27.59
Upside: -49.26%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $12.26
Upside: +430.18%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.01
Upside: +99.60%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.37
Upside: +107.25%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.92
Upside: +51,269.86%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.13
Upside: +477,776.11%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $1.83
Upside: +501.09%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.34
Upside: +438.92%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $7.44
Upside: +572.04%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.61
Upside: +528,793.24%